NeuroOne Medical Technologies Q3 2026 Earnings Report

NeuroOne Medical Technologies EPS Results

• Actual EPS: N/A
• Consensus EPS: -$0.58
• Beat/Miss: N/A
• One Year Ago EPS: N/A

NeuroOne Medical Technologies Revenue Results

• Actual Revenue: N/A
• Expected Revenue: $2.55 million
• Beat/Miss: N/A
• YoY Revenue Growth: N/A

NeuroOne Medical Technologies Announcement Details

• Quarter: Q3 2026
• Date: 8/13/2026
• Time: Before Market Opens
• Conference Call Date: Thursday, August 13, 2026
• Conference Call Time: 8:30AM ET

NeuroOne Medical Technologies (NASDAQ:NMTC) Corp. is a medical device company focused on developing advanced neural interface technologies for diagnostic and therapeutic applications in neurosurgery and neurology. The company’s core mission is to improve patient outcomes through next-generation electrode systems that enable high-resolution neural recording and targeted stimulation. By leveraging proprietary thin-film microelectrode arrays, NeuroOne aims to offer clinicians unprecedented single-unit precision during brain mapping procedures.

The company’s flagship platform, the EVO™ system, integrates thin-film neural electrodes with intraoperative monitoring hardware and software. This system is designed to assist neurosurgeons in procedures such as epilepsy monitoring and deep brain stimulation planning by providing real-time, high-fidelity recordings of neuronal activity. NeuroOne also supports research partnerships with leading academic medical centers to explore applications of its technology in movement disorders and neurological disorders.

Founded as a spin-out of Mayo Clinic research, NeuroOne has advanced its technology through rigorous preclinical studies and regulatory review. In September 2023, the U.S. Food and Drug Administration granted 510(k) clearance for the EVO™ intraoperative neuromonitoring system. The company is headquartered in Eden Prairie, Minnesota, and operates a research and development facility in the same region to drive continuous innovation.

Under the leadership of President and CEO Rajendra S. Singh, MD, a neurosurgeon with extensive clinical experience, NeuroOne is executing a commercial rollout of its platform across North America. The company is actively engaging with key opinion leaders, surgical centers, and research institutions to establish its technology as a new standard for neural interface procedures. Looking ahead, NeuroOne aims to expand its geographic footprint and pursue additional regulatory approvals to broaden clinical access to its solutions.